THE "NEW" PROSTATE CANCER INFOLINK

We have already mentioned the article on genomics and biomarkers in this month’s issue of AUA News, but there are two other articles in this issue of the publication that are likely to be of interest to at least some of our regular readers.

The first of these articles, by Wang and Dhanani, appears under the heading “Phosphodiesterase type 5 inhibitor therapy for the post-pelvic surgical patient” (see p. 8 of this issue of AUA News) and deals specifically with the role of daily as opposed to “on demand” use of drugs like Viagra and Cialis in management of penile rehabilitation and post-surgical erectile function.

The second article, by Malaeb, is entitled “Contemporary management of post-prostatectomy incontinence — is the artificial urinary sphincter still the gold standard” (see p. 10 of this issue). This article addresses the ongoing evolution of strategies to manage those patients with less that ideal continence after initial recovery from radical prostatectomy. As Dr. Malaeb carefully notes, this is complicated by the (arguably unnecessary) lack of consensus about definitions  — of severity of incontinence, of success after surgery, and of the use of urinary incontinence-specific, patient-reported outcomes and quality of life data.

Filed under: Living with Prostate Cancer | Tagged: dysfunction, erectile, incontinence, prostatectomy, sexual, side effect, surgery |